

PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: J Biol Chem. 1987 Jul 25;262(21):9935-8.

Related Article

FREE full text article at
www.jbc.org**Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix.****Charo IF, Bekeart LS, Phillips DR.**

The adherence of human umbilical vein endothelial (HUVE) cells to adhesive matrix proteins was examined to determine if cell attachment and spreading were mediated by the glycoprotein (GP) IIb-IIIa complex on endothelial cells. The HUVE cells adhered well to glass slides that had been coated with fibronectin, vitronectin, fibrinogen, or von Willebrand factor but failed to adhere to albumin-coated or to uncoated slides. The HUVE cell attachment and spreading on vitronectin, fibrinogen, and von Willebrand factor were greatly inhibited by a GP IIb-IIIa monoclonal antibody (7E3). In contrast, HUVE cell attachment to fibronectin was not inhibited by 7E3 but was inhibited by a fibronectin-receptor antibody (alpha GP140), which had no effect on cell attachment to the other adhesive proteins. The 7E3 antibody, but not alpha GP140, disrupted HUVE monolayers by detaching cells from their naturally occurring extracellular matrix. These data indicate that platelet GP IIb-IIIa-like proteins mediate the adherence of HUVE cells to specific adhesive proteins and to the extracellular matrix.

PMID: 2440865 [PubMed - indexed for MEDLINE]

Display

Abstract

Show:

20


Sort

Send to

Text

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act](#) | [Disclaimer](#)

Aug 6 2003



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search

PubMed



for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract



Show:

20



Sort



Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Biochem J. 1993 Jan 15;289 (Pt 2):445-51.

Related Article

Evidence for novel binding sites on the platelet glycoprotein IIb IIIa subunits and immobilized fibrinogen.**Parise LV, Steiner B, Nannizzi L, Criss AB, Phillips DR.**

Gladstone Institute of Cardiovascular Disease, University of California, San Francisco 94141-9100.

The present study was designed to examine the interaction of the purified platelet glycoprotein IIb-IIIa complex (GP IIb-IIIa or integrin alpha IIb beta 3) and the individual subunits of the complex with immobilized fibrinogen. Although 1:1 GP IIb-IIIa binding to fibrinogen immobilized on Sepharose was specific, this interaction exhibited properties distinct from those of reversible fibrinogen binding to platelets: 125I-GP IIb-IIIa binding appeared irreversible, but non-covalent (2+)-independent, and was inhibited only weakly, or not at all, by the anti-(GP IIIa) monoclonal antibodies 10E5 and 7E3 and synthetic peptides from known platelet-binding domains of fibrinogen. Reversibly dissociated GP IIb or GP IIIa subunits inhibited 125I-GP IIb-IIIa binding to immobilized fibrinogen and bound directly to the fibrinogen. However, these subunits did not bind to peptides derived from known platelet-binding domains within the fibrinogen alpha- and gamma chains, although the GP IIb-IIIa complex did. These results show that the complexed form of full-length GP IIb and GP IIIa is required for binding to the synthetic peptides, but not necessarily for binding to immobilized fibrinogen. GP IIb-IIIa can bind to immobilized fibrinogen by a distinct mechanism that appears to involve novel binding sites on each subunit of the GP IIb-IIIa complex and on fibrinogen.

PMID: 8424789 [PubMed - indexed for MEDLINE]

Display

Abstract



Show:

20



Sort



Send to

Text

[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)

Department of Health & Human Services

ANTICANCER DRUGS 1996 7:723-7



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

☐ 1: Br J Cancer. 1998 Mar;77(6):956-64.

Related Article

Comment in:

- Br J Cancer. 1999 Jan;79(2):370-3.

Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements in cancer biology.

Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Sell

ICRF Cancer Medicine Research Unit, St James's University Hospital, Leeds

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor with key role in several pathological processes, including tumour vascularization. preliminary observations indicated higher VEGF concentrations in serum than in matched plasma samples. We have now demonstrated that this difference due to the presence of VEGF within platelets and its release upon their activation during coagulation. In eight healthy volunteers, serum VEGF concentrations ranged from 76 to 854 pg ml⁻¹ and were significantly higher ($P < 0.01$) than matched citrated plasma VEGF concentrations, which ranged from < 9 to 42 pg ml⁻¹. Using platelet-rich plasma, mean (s.d.) platelet VEGF contents of 0.56 (pg of VEGF 10(-6) platelets were found. Immunocytochemistry demonstrate cytoplasmic presence of VEGF within megakaryocytes and other cell types in the bone marrow. From examination of the effects of blood sample processing on circulating VEGF concentrations, it is apparent that for accurate measurement citrated plasma processed within 1 h of venepuncture should be used. Serum completely unsuitable. The presence of VEGF within platelets has implications for processes involving platelet and endothelial cell interactions. e.g. wound healing and in tumour metastasis, when platelets adhering to circulating tumour cells release VEGF at points of adhesion to endothelium, leading to hyperpermeability and extravasation of cells.

PMID: 9528841 [PubMed - indexed for MEDLINE]

Display

Abstract

Show:

20

Sort

Send to

Text

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=95288... 8/13/03

*
PNAS 1/1997
94: 663-8

CLIN CANCER RES

12/1997 3: 2187-90

EUR J CANCER
1996 32A 2401-12



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search

PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract

Show:

20

Sort

Send to

Text

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Privacy Policy

1: Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90.

Related Article

Platelet: transporter of vascular endothelial growth factor.**Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC Broxterman HJ, Pinedo HM.**

Department of Medical Oncology, University Hospital "Vrije Universiteit," 1 MB Amsterdam, The Netherlands.

In animal models, growth of tumors and their metastases is dependent on factors that stimulate vessel formation (angiogenesis). Most clinical studies confirm importance of angiogenesis for cancer growth in patients. Recent studies on circulating angiogenic factors in patients have focused on serum vascular endothelial growth factor (VEGF) levels in a variety of cancer types. We measured serum VEGF concentrations and blood counts in 27 breast cancer patients during each of 6 cycles of chemotherapy with doxorubicin and cyclophosphamide supported by granulocyte macrophage colony-stimulating factor. Serum VEGF concentrations highly correlated with platelet counts during chemotherapy ($r = 0.9$; $P < 0.01$). In particular, during the first treatment cycle, after an initial episode of thrombocytopenia, a strong platelet rebound coincided closely with a serum VEGF peak ($r = 0.9$; $P < 0.01$). In addition, plasma VEGF concentrations from 15 cancer patients and 30 healthy volunteers were 5- to 8-fold lower than their corresponding serum VEGF concentrations ($P < 0.001$). Activation of platelets increased the VEGF content 8-10 times. These findings demonstrate that VEGF released by platelets during serum preparation. In this study, we found evidence for VEGF transport by platelets, indicating that serum VEGF concentrations reflect mainly platelet counts rather than tumor burden in cancer patients, as reported earlier. Platelets, known to be important for wound healing, have also been reported to contribute to metastasis formation and tumor growth in animal models. Indeed, tumors can be regarded as never-healing wounds. Our data suggest that platelets may have a stimulating role on angiogenesis-dependent tumor growth through their function as transporters of VEGF.

PMID: 9815613 [PubMed - indexed for MEDLINE]

ANGIOGENESIS + LUNG
+ VITROGENESIS

INT J CANCER 1997 71:320-4

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9815613 8/13/03

J CLIN INVEST 96:1815-22 1995

LANCET 1996
352:1775